Ever Fortune.AI Valuation
Is 6841 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 6841 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 6841 (NT$75.4) is trading above our estimate of fair value (NT$14.06)
Significantly Below Fair Value: 6841 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 6841?
Key metric: As 6841 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 6841's PS Ratio? | |
|---|---|
| PS Ratio | 26.4x |
| Sales | NT$277.66m |
| Market Cap | NT$7.33b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 23.2x |
| Enterprise Value/EBITDA | -1225.2x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 6841's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 14.9x | ||
6569 Onyx Healthcare | 4.4x | n/a | NT$5.7b |
6857 Acer Medical | 48.1x | n/a | NT$2.2b |
8409 EBM Technologies | 3.5x | n/a | NT$700.8m |
4771 Vizionfocus | 3.6x | 16.5% | NT$11.0b |
6841 Ever Fortune.AI | 26.4x | n/a | NT$7.3b |
Price-To-Sales vs Peers: 6841 is expensive based on its Price-To-Sales Ratio (26.4x) compared to the peer average (14.9x).
Price to Sales Ratio vs Industry
How does 6841's PS Ratio compare vs other companies in the Asian Healthcare Services Industry?
| 4 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 4 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: 6841 is expensive based on its Price-To-Sales Ratio (26.4x) compared to the Asian Healthcare Services industry average (4.7x).
Price to Sales Ratio vs Fair Ratio
What is 6841's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 26.4x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 6841's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Universal Vision Biotechnology
NT$17.8b
Operates a chain of eye care clinics in Taiwan and China.
3218
NT$210.50
7D
-4.1%
1Y
-25.1%
Hi-Clearance
NT$6.2b
Supplies medical devices for the renal, cardiac, radiation, dental, oral surgery, and metabolism markets in Taiwan.
1788
NT$138.50
7D
-0.4%
1Y
1.5%
Ma Kuang Healthcare Holding
NT$1.3b
An investment holding company, provides medical services in Taiwan and internationally.
4139
NT$30.35
7D
1.0%
1Y
-19.1%